KRAS and glioblastoma: Such screens have been used to identify cellular signalling pathways that cause resistance to immunotherapy in the context of melanoma [68], to identify liver tumour suppressors [69], to identify suppressors in glioblastoma [70] and to study essential genes in the context of mutant KRAS colorectal cancers [71].